Babcock Genetics, Inc.

babcockgenetics.com

Babcock Genetics, Inc. is a leading supplier of swine genetics to the United States commercial industry. By utilizing cutting edge research methods, superior swine genetics, and a closed herd system, Babcock supplies its customers with a genetic base with a high probability for profitability. Babcock is an innovative company that is committed to all facets of the pork industry in addition to its own success. Minimum disease risk, excellent reproductive performance, growth rate, feed efficiency, and pork quality best describe Babcock Genetics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

BIO-TECHNE AND CARTERRA INITIATE A CLINICAL RESEARCH COLLABORATION FOR COVID-19 VARIANT ANALYSIS

Bio-Techne Corporation | September 08, 2021

news image

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to ...

Read More

Research, Industry Outlook

BIGHAT BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH MERCK

BigHat Biosciences, Inc. | November 30, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better...

Read More

Regulatory

LUMMUS AND BRASKEM ANNOUNCE PARTNERSHIP FOR GREEN ETHYLENE TECHNOLOGY

Braskem | April 29, 2022

news image

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...

Read More

Medical, Industry Outlook

REGENXBIO ANNOUNCES NAV® TECHNOLOGY PLATFORM WILL SUPPORT BESPOKE GENE THERAPY CONSORTIUM'S FIRST RARE DISEASE CLINICAL PORTFOLIO

PRNewswire | May 17, 2023

news image

REGENXBIO Inc. announced that preclinical research in Mucopolysaccharidosis type IVA also known as Morquio syndrome, was selected for inclusion in the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC), clinical trial portfolio. The Consortium brings together partners such as NIH and FDA, as well as partners from private and non-profit sectors. Sponsored by Nemours Children's Hospital, MPS ...

Read More
news image

Research

BIO-TECHNE AND CARTERRA INITIATE A CLINICAL RESEARCH COLLABORATION FOR COVID-19 VARIANT ANALYSIS

Bio-Techne Corporation | September 08, 2021

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants. New variants, such as Delta, can be more easily transmitted and more likely to evade the immune response of vaccinated or previously infected people. To assess immune responses to ...

Read More
news image

Research, Industry Outlook

BIGHAT BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH MERCK

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better...

Read More
news image

Regulatory

LUMMUS AND BRASKEM ANNOUNCE PARTNERSHIP FOR GREEN ETHYLENE TECHNOLOGY

Braskem | April 29, 2022

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...

Read More
news image

Medical, Industry Outlook

REGENXBIO ANNOUNCES NAV® TECHNOLOGY PLATFORM WILL SUPPORT BESPOKE GENE THERAPY CONSORTIUM'S FIRST RARE DISEASE CLINICAL PORTFOLIO

PRNewswire | May 17, 2023

REGENXBIO Inc. announced that preclinical research in Mucopolysaccharidosis type IVA also known as Morquio syndrome, was selected for inclusion in the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC), clinical trial portfolio. The Consortium brings together partners such as NIH and FDA, as well as partners from private and non-profit sectors. Sponsored by Nemours Children's Hospital, MPS ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us